[Research Articles] Neuronal delivery of antibodies has therapeutic effects in animal models of botulism

Botulism is caused by a potent neurotoxin that blocks neuromuscular transmission, resulting in death by asphyxiation. Currently, the therapeutic options are limited and there is no antidote. Here, we harness the structural and trafficking properties of an atoxic derivative of botulinum neurotoxin (BoNT) to transport a function-blocking single-domain antibody into the neuronal cytosol where it can inhibit BoNT serotype A (BoNT/A1) molecular toxicity. Post-symptomatic treatment relieved toxic signs of botulism and rescued mice, guinea pigs, and nonhuman primates after lethal BoNT/A1 challenge. These data demonstrate that atoxic BoNT derivatives can be harnessed to deliver therapeutic protein moieties to the neuronal cytoplasm where they bind and neutralize intracellular targets in experimental models. The generalizability of this platform might enable delivery of antibodies and other protein-based therapeutics to previously inaccessible intraneuronal targets.

Source: Science Translational Medicine - January 6, 2021 Category: Biomedical Science Authors: McNutt, P. M., Vazquez-Cintron, E. J., Tenezaca, L., Ondeck, C. A., Kelly, K. E., Mangkhalakhili, M., Machamer, J. B., Angeles, C. A., Glotfelty, E. J., Cika, J., Benjumea, C. H., Whitfield, J. T., Band, P. A., Shoemaker, C. B., Ichtchenko, K. Tags: Research Articles Source Type: research